ArticleBritish journal of pharmacology2008
Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice.
Article in British journal of pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02584439 (Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)
Who cites it
28 citing papers in PubMed, 95 citations in OpenAlex.
- Trial
- Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study.Clinical research in cardiology : official journal of the German Cardiac Society · 2017Trial
- β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index.Clinical research in cardiology : official journal of the German Cardiac Society · 2016Trial
- Effect of ivabradine-induced heart rate reduction on flow-mediated dilation measured with high-sensitivity ultrasound in patients with stable coronary heart disease.Cardiovascular ultrasound · 2014Trial
- Resting heart rate (variability) and cognition relationships reveal cognitively healthy individuals with pathological amyloid/tau ratio.Frontiers in epidemiology · 2023Article
- Ivabradine Ameliorates Kidney Fibrosis in L-NAME-Induced Hypertension.Frontiers in medicine · 2020Article
- The effect of the heart rate lowering drug Ivabradine on hemodynamics in atherosclerotic mice.Scientific reports · 2018Article
- Cerebral Vascular Disease and Neurovascular Injury in Ischemic Stroke.Circulation research · 2017Review
- Review
- Advances in the management of heart failure: the role of ivabradine.Vascular health and risk management · 2016Review
- Ivabradine Prevents Low Shear Stress Induced Endothelial Inflammation and Oxidative Stress via mTOR/eNOS Pathway.PloS one · 2016Article
- I(f) current channel inhibitor (ivabradine) deserves cardioprotective effect via down-regulating the expression of matrix metalloproteinase (MMP)-2 and attenuating apoptosis in diabetic mice.BMC cardiovascular disorders · 2014Article
- Ivabradine improves heart rate variability in patients with nonischemic dilated cardiomyopathy.Arquivos brasileiros de cardiologia · 2014Article
- Lack of angiopoietin-like-2 expression limits the metabolic stress induced by a high-fat diet and maintains endothelial function in mice.Journal of the American Heart Association · 2014Article
- Ivabradine therapy to unmask heart rate-independent effects of β-blockers on pulse wave reflections.Clinical research in cardiology : official journal of the German Cardiac Society · 2014Article
- Ivabradine, coronary artery disease, and heart failure: beyond rhythm control.Drug design, development and therapy · 2014Review
- Review
- The biological effects of ivabradine in cardiovascular disease.Molecules (Basel, Switzerland) · 2012Review
- Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis.PloS one · 2012Article
- Heart rate-associated mechanical stress impairs carotid but not cerebral artery compliance in dyslipidemic atherosclerotic mice.American journal of physiology. Heart and circulatory physiology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeHigh resting heart rate is a predictor for total and cardiovascular mortality independent of other risk factors in patients with coronary artery disease. We tested the hypothesis that a reduction of resting heart rate with the cardiac pacemaker I(f) current inhibitor ivabradine prevents the endothelial dysfunction associated with dyslipidaemia. EXPERIMENTAL APPROACH: Three-month-old dyslipidaemic (DL) male mice expressing the human ApoB-100 were assigned or not (DL, n=16), to treatment for 3 months with ivabradine (10 mg kg(-1) d(-1), n=17). Wild-type C57Bl/6 mice (WT, n=15) were used as controls. Heart rate was measured at 3, 4.5 and 6 months. Dilatation to acetylcholine (ACh) of isolated cerebral and renal arteries was investigated at 6 months. KEY
resultsHeart rate remained stable in anaesthetized WT mice, increased (25%, P<0.05) with age in DL mice but was limited (11%, P<0.05) by ivabradine. At 6 months, left ventricular maximal pressure was similar in all groups. The minimal and end-diastolic left ventricular pressures were increased (P<0.05) in DL (10.2+/-1.0 and 18.7+/-1.4 mm Hg) compared to WT (-0.4+/-0.7 and 6.3+/-1.0 mm Hg) and reduced (P<0.05) by ivabradine (4.2+/-1.3 and 11.5+/-1.5 mm Hg). ACh-induced maximal dilatation was impaired (P<0.05) in renal and cerebral arteries isolated from DL compared to WT (56+/-7 versus 83+/-3% in renal arteries; 22+/-2 versus 42+/-2% in cerebral arteries). Ivabradine completely prevented (P<0.05) this dysfunction in renal and cerebral arteries. CONCLUSIONS AND IMPLICATIONS: Selective heart rate reduction with ivabradine limits cardiac dysfunction and prevents the renovascular and cerebrovascular endothelial dysfunction associated with dyslipidaemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.